- Login
- Register & Subscribe
- Langue: EN FR DE
Therapies derived from human embryonic stem (hES) cells promise to be the most stable and cost-effective modality for future medicines and deserve support from public and private funders, according to a commentary in The Lancet.
United Kingdom
Monday May 6 2013
Monday May 6 2013
Monday May 6 2013
Monday May 6 2013
Monday May 6 2013